← Back to all trials
Not Yet Recruiting
NCT07706166
Letermovir for R+ Study
Conditions: Kidney Transplant, Liver Transplant
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 146
Sponsor: University of Wisconsin, Madison
Location: University of Wisconsin - Madison Madison Wisconsin
Summary
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.
Participants will take letermovir for 84 days.
Eligibility Criteria
Inclusion Criteria:
* Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
* Adults who received a kidney transplant, liver transplant, or any combination thereof
Exclusion Criteria:
* Known contraindication to letermovir or its excipients
* Current participation in another CMV related study
* Unwilling or unable to participate in the study protocol
Source: ClinicalTrials.gov (NCT07706166). StuddyBuddy aggregates publicly available trial information.
